Results for Drug Benefits and Risk

David Teachey, MD, and colleagues are exploring convalescent plasma as a treatment for COVID-19, the disease caused by SARS-CoV-2.

Options to ship study drugs during COVID-19

In the News announces the Research Institute’s 2019 Annual Report and shares research highlights to start off the holiday season.

The 2019 Scientific Symposium focused on the advances CHOP researchers have made in the booming area of genomics and data science.

In this week’s recap, our researchers make headlines with their work in endocrinology, autism research, telehealth, the gut-brain connection, and more.

New preclinical findings from extensive cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with some mitochondrial disorders—complex conditions with severe energy deficiency for which no proven effective treatments exist. Future clinical research is needed to explore whether the drug, cysteamine bitartrate, will meaningfully benefit patients.

In this week’s recap, collaboration at the local and international levels takes center stage.

In this week’s research roundup: personalized gene therapies reach key milestones and scientists probe CAR T-cell resistance.

An infographic and article look at the science behind gene therapy, challenges faced by the field, and the road ahead.

Drs. Jorge Henao-Mejia, Sarah Henrickson, and Elizabeth Bhoj received highly competitive awards for their game-changing research.